ES2597832T3 - Vacuna acelular contra la tosferina - Google Patents

Vacuna acelular contra la tosferina Download PDF

Info

Publication number
ES2597832T3
ES2597832T3 ES14708064.2T ES14708064T ES2597832T3 ES 2597832 T3 ES2597832 T3 ES 2597832T3 ES 14708064 T ES14708064 T ES 14708064T ES 2597832 T3 ES2597832 T3 ES 2597832T3
Authority
ES
Spain
Prior art keywords
pertussis
vaccine against
fim
acellular vaccine
against pertussis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14708064.2T
Other languages
English (en)
Inventor
Jan Theunis Poolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Janssen Vaccines and Prevention BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines and Prevention BV filed Critical Janssen Vaccines and Prevention BV
Application granted granted Critical
Publication of ES2597832T3 publication Critical patent/ES2597832T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una composición de vacuna acelular contra la tosferina (aP) que comprende los antígenos de B. Bordetella pertussis, toxoide de pertussis (PT), hemaglutinina filamentosa (FHA) y los tipos de fimbrias (FIM) 2 y 3, y, opcionalmente, pertactina (PRN), en la que FIM está presente en una cantidad de 12-100 μg 5 por dosis humana.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
16
Tabla 4: Niveles de anticuerpos anti-FIM y títulos de aglutinación contra un panel de cepas de B. pertussis determinados en mezclas de sueros recogidos de 5 ratones por grupo vacunados a las 4 y 7 semanas de edad con 1/10 de la dosis humana de aP2 con o sin la adición de FIM. Véanse detalles en el ejemplo 5.
17

Claims (1)

  1. imagen1
ES14708064.2T 2013-03-08 2014-03-06 Vacuna acelular contra la tosferina Active ES2597832T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361774993P 2013-03-08 2013-03-08
US201361774993P 2013-03-08
EP13169328 2013-05-27
EP13169328 2013-05-27
PCT/EP2014/054379 WO2014135651A1 (en) 2013-03-08 2014-03-06 Acellular pertussis vaccine

Publications (1)

Publication Number Publication Date
ES2597832T3 true ES2597832T3 (es) 2017-01-23

Family

ID=48470836

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14708064.2T Active ES2597832T3 (es) 2013-03-08 2014-03-06 Vacuna acelular contra la tosferina

Country Status (22)

Country Link
US (2) US8916173B2 (es)
EP (1) EP2863943B1 (es)
JP (1) JP6282673B2 (es)
KR (1) KR102236498B1 (es)
CN (1) CN105007936B (es)
AP (1) AP2015008702A0 (es)
AU (1) AU2014224556B2 (es)
BR (1) BR112015021523A8 (es)
CA (1) CA2903937C (es)
CL (1) CL2015002513A1 (es)
DK (1) DK2863943T3 (es)
EA (1) EA030749B1 (es)
ES (1) ES2597832T3 (es)
IL (1) IL241271A (es)
MX (1) MX362793B (es)
MY (1) MY172181A (es)
NZ (1) NZ630868A (es)
PE (1) PE20151720A1 (es)
PH (1) PH12015501875A1 (es)
SG (1) SG11201506858SA (es)
TW (1) TWI630915B (es)
WO (1) WO2014135651A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
RU2596919C2 (ru) * 2015-01-16 2016-09-10 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка
KR102426041B1 (ko) 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
KR102362777B1 (ko) 2018-03-27 2022-02-15 주식회사 녹십자 친화성 크로마토그래피 공정을 포함하는 백일해균 유래 단백질 수득 방법
CN112996538A (zh) * 2018-11-06 2021-06-18 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
CN111053898B (zh) * 2019-12-26 2023-05-16 北京科兴中维生物技术有限公司 一种疫苗组合物及其应用
US20230072809A1 (en) * 2020-03-09 2023-03-09 Dynavax Technologies Corporation Active booster immunization against tetanus, diphtheria and pertussis
WO2024064579A1 (en) * 2022-09-20 2024-03-28 Ohio State Innovation Foundation Immunogenic proteins from bordetella pertussis
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
GB8412207D0 (en) 1984-05-12 1984-06-20 Wellcome Found Antigenic preparations
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8516442D0 (en) 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3528006A1 (de) 1985-08-05 1987-02-05 Degussa Verfahren zur herstellung von epoxidierten organosiliziumverbindungen
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
GB8601279D0 (en) 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
ES2044959T3 (es) 1986-12-23 1994-01-16 Univ Leland Stanford Junior Exotoxina de tos ferina modificada.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
ATE105858T1 (de) 1987-07-17 1994-06-15 Rhein Biotech Ges Fuer Biotech Dna-moleküle, die für fmdh-kontrollabschnitte und strukturgene für ein protein mit fmdh-aktivität kodieren, sowie deren anwendung.
US7144576B1 (en) 1987-09-04 2006-12-05 Amgen, Inc. Modified pertussis toxin
KR0168039B1 (ko) 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
IT1223334B (it) 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA1341123C (en) 1988-10-27 2000-10-17 David A. Relman Filamentous hemagglutinin of b. pertussis
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
ES2078258T3 (es) 1989-04-28 1995-12-16 Sclavo Spa Mutantes de toxina pertussica, cepas de bordetella capaces de producir tales mutantes y su uso en el desarrollo de vacunas antipertussicas.
GB8910570D0 (en) 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
ES2084668T3 (es) 1989-11-06 1996-05-16 Smithkline Beecham Biolog Procedimiento.
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
EP0515415B1 (en) 1990-02-12 1995-10-18 SMITHKLINE BEECHAM BIOLOGICALS s.a. Novel vaccine and method therefor
GB9007657D0 (en) 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6444211B2 (en) 1991-04-03 2002-09-03 Connaught Laboratories, Inc. Purification of a pertussis outer membrane protein
AU662783B2 (en) 1992-01-08 1995-09-14 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Whooping cough vaccine
CA2135052A1 (en) 1992-05-06 1993-11-11 R. John Collier Diphtheria toxin receptor-binding region
PT835663E (pt) 1992-05-23 2010-01-04 Glaxosmithkline Biolog Sa Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios
WO1993025210A1 (en) 1992-06-18 1993-12-23 President And Fellows Of Harvard College Diphtheria toxin vaccines
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FI951970A (fi) 1995-04-25 1996-10-26 Borealis As Olefiinipolymeerit, jotka sisältävät polaarisia ryhmiä, ja menetelmä niiden valmistamiseksi
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
EP1234580A1 (en) 1995-05-04 2002-08-28 Aventis Pasteur Limited Acellular Pertussis Vaccines and Methods of Preparation Thereof
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
RU2194531C2 (ru) 1996-07-02 2002-12-20 Коннот Лабораториз Лимитед Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно (акдс)-полиомиелитные вакцины
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US6475754B1 (en) 1999-05-14 2002-11-05 University Of Tennessee Research Corporation Polynucleotides encoding Bordatella bronchiseptica fimbrial proteins (FimN), vectors, and expression systems therefor
AP1695A (en) 2000-06-29 2006-12-17 Glaxosmithkline Biologicals Sa Multivalent vaccine composition.
EP1174505A1 (en) * 2000-06-30 2002-01-23 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur (Poly)peptides for the preparation of vaccines against Bordetella pertussis and/or Bordetella parapertussis, vaccines based upon such (poly)peptides, and antibodies against such peptides
GB0018031D0 (en) 2000-07-21 2000-09-13 Microbiological Res Authority Improvements relating to vaccines containing bordetella pertussis antigen
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
MX2009002560A (es) 2006-09-07 2009-03-20 Glaxosmithkline Biolog Sa Vacuna.
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
MY183385A (en) 2009-07-16 2021-02-18 Janssen Vaccines & Prevention Bv Production of polio virus at high titers for vaccine production
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant

Also Published As

Publication number Publication date
CN105007936A (zh) 2015-10-28
CA2903937A1 (en) 2014-09-12
US8916173B2 (en) 2014-12-23
MY172181A (en) 2019-11-15
EA030749B1 (ru) 2018-09-28
EA201591663A1 (ru) 2016-01-29
US20140255446A1 (en) 2014-09-11
WO2014135651A1 (en) 2014-09-12
NZ630868A (en) 2017-02-24
TWI630915B (zh) 2018-08-01
KR102236498B1 (ko) 2021-04-06
JP2016510056A (ja) 2016-04-04
BR112015021523A8 (pt) 2021-06-29
AP2015008702A0 (en) 2015-09-30
MX2015011879A (es) 2016-01-08
CA2903937C (en) 2021-11-09
IL241271A0 (en) 2015-11-30
TW201440786A (zh) 2014-11-01
AU2014224556A1 (en) 2015-09-17
CL2015002513A1 (es) 2016-05-27
DK2863943T3 (en) 2016-11-07
EP2863943A1 (en) 2015-04-29
US20150086586A1 (en) 2015-03-26
PH12015501875A1 (en) 2015-12-07
MX362793B (es) 2019-02-13
SG11201506858SA (en) 2015-09-29
KR20150124973A (ko) 2015-11-06
IL241271A (en) 2016-07-31
AU2014224556B2 (en) 2016-10-06
EP2863943B1 (en) 2016-07-13
JP6282673B2 (ja) 2018-02-21
PE20151720A1 (es) 2015-12-10
CN105007936B (zh) 2018-10-02
BR112015021523A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
ES2597832T3 (es) Vacuna acelular contra la tosferina
Hegerle et al. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
CY1117874T1 (el) Χρηση ενος ιου γριπης και ενος ανοσοενισχυτικου γαλακτωματος ελαιου-σε-νερο για την προκλιση αποκρισης των cd4 τ-κυτταρων και/ή βελτιωμενη αποκριση των β-κυτταρων μνημης
CY1114864T1 (el) Συνθεσεις εμβολιου οι οποιες περιεχουν ανοαοενισχυτικο εκδοχο σαπωνινης
WO2017096341A3 (en) Adenovirus-vectored multivalent vaccine
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
BR112015009070A2 (pt) proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas
Kasi et al. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): recommended immunization schedule (2020–21) and update on immunization for children aged 0 through 18 years
PE20100366A1 (es) Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
AR102548A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
AR100740A1 (es) Vacunas dirigidas por anticuerpos y sus métodos de uso para generar respuestas inmunes maduras rápidas
MX2015009507A (es) Antigenos recombinantes del porcine circovirus 2 (pcv-2) para formulaciones de vacuna, kit de diagnostico y uso.
AR115069A1 (es) Virus vacuna quimérico sintético
AR088907A1 (es) Vacuna
BR112014020025A8 (pt) Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
Li et al. Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen
AR117191A1 (es) Composiciones inmunogénicas
AR106501A1 (es) Adyuvante y composición de vacuna que lo contiene
BR112017004703A2 (pt) ?vacina e método para proteção de progênie de uma porca contra infeccção por um vírus de diarreia endêmica suína?
AR088908A1 (es) Vacuna
AR095206A1 (es) Vacuna acelular contra pertussis